PHOENIX ― Gastrointestinal cancers are some of the most commonly diagnosed cancers, and they continue to be associated with poor survival outcomes. The drug adagrasib specifically targets the KRASG12C gene mutation that is common in gastrointestinal cancers and inhibits gastrointestinal function.
Trending
- Where GI practices are struggling, succeeding (Becker’s GI & Endoscopy)
- Physician shortage and private equity: the ruin of U.S. health care (KevinMD)
- Why leading physicians will move to concierge medicine in 2026 with Greg Grant of Specialdocs (Physicians Practice)
- Nanorobots hold PD-L1 and break membrane of colorectal cancer cells for immunotherapy (Nature)
- Stiffer colon could signal risk of early-onset colorectal cancer (Medical Xpress)
- Successful GI Sign-off Protocol Incorporates Primary Care Feedback (GI & Endoscopy News)
- Earlier and More Intensive Advanced Therapy Use Fails to Improve 10-Year Crohn’s Outcomes (Docwire News)
- CMS Launches WISeR Model: New Medicare Prior Authorization Rules Start Jan. 1 (HIT Consultant)
